Objective To address the personalized differences in motion gait between stroke patients and healthy older adults,as well as the issue of abnormal gait recognition,a deep learning fusion-based approach is proposed to effectively improve the accuracy of abnormal gait recognition.Methods A model fusing convolutional neural networks(CNN)and bidirectional long short-term memory networks(BiLSTM)was adopted,with the introduction of a residual network(ResNet).Unilateral ankle joint movement data at different walking speeds within a comfortable range were collected from healthy older adults and stroke patients.Signals from inertial sensors and electromyography sensors were used as inputs,while gait features were analyzed and gait differences between the two groups were compared.The effectiveness of the model was validated by comparing the classification performance of traditional deep learning models and CNN-ResNet-BiLSTM models with different layer combinations in terms of abnormal gait recognition accuracy.Results The CNN-ResNet-BiLSTM model,which introduced residual connectivity,performed excellently in abnormal gait recognition.Compared with traditional deep learning models such as the gated recurrent unit(GRU)and long short-term memory network(LSTM),its prediction accuracy was improved by 13.6％and 8.36％,respectively.Additionally,compared with other model combinations,this model achieved an overall accuracy of 97.78％.Conclusions The algorithm proposed in this study can be applied to stroke-related abnormal gait detection,providing technique support for the early diagnosis and precise monitoring of such diseases.

Ursodeoxycholic acid (UDCA) is a naturally occurring, low-toxicity, and hydrophilic bile acid (BA) in the human body that is converted by intestinal flora using primary BA. Solute carrier family 7 member 11 (SLC7A11) functions to uptake extracellular cystine in exchange for glutamate, and is highly expressed in a variety of human cancers. Retroperitoneal liposarcoma (RLPS) refers to liposarcoma originating from the retroperitoneal area. Lipidomics analysis revealed that UDCA was one of the most significantly downregulated metabolites in sera of RLPS patients compared with healthy subjects. The augmentation of UDCA concentration (≥25 μg/mL) demonstrated a suppressive effect on the proliferation of liposarcoma cells. [¹⁵N₂]-cystine and [¹³C₅]-glutamine isotope tracing revealed that UDCA impairs cystine uptake and glutathione (GSH) synthesis. Mechanistically, UDCA binds to the cystine transporter SLC7A11 to inhibit cystine uptake and impair GSH de novo synthesis, leading to reactive oxygen species (ROS) accumulation and mitochondrial oxidative damage. Furthermore, UDCA can promote the anti-cancer effects of ferroptosis inducers (Erastin, RSL3), the murine double minute 2 (MDM2) inhibitors (Nutlin 3a, RG7112), cyclin dependent kinase 4 (CDK4) inhibitor (Abemaciclib), and glutaminase inhibitor (CB839). Together, UDCA functions as a cystine exchange factor that binds to SLC7A11 for antitumor activity, and SLC7A11 is not only a new transporter for BA but also a clinically applicable target for UDCA. More importantly, in combination with other antitumor chemotherapy or physiotherapy treatments, UDCA may provide effective and promising treatment strategies for RLPS or other types of tumors in a ROS-dependent manner.

Objective:To investigate the effects of different doses of rosuvastatin on lipid metabolism and left ventricular function in patients with type 2 diabetes mellitus (T2DM) accompanied by coronary heart disease (CHD).Methods:A prospective study was conducted involving 63 patients with T2DM accompanied by CHD who were treated at Jinan 2 nd People's Hospital and The Fifth People's Hospital of Jinan from January 2022 to June 2023. In a randomized case-control study, patients were assigned to either a control group ( n = 31, receiving 10 mg/d of rosuvastatin) or an observation group ( n = 32, receiving 20 mg/d of rosuvastatin) using a random number table method. After 8 weeks of treatment, the therapeutic effects were evaluated, and blood lipid levels and left ventricular function were recorded before and after treatment. Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), homocysteine (Hcy), C-reactive protein (CRP), and the distance covered in a 6-minute walk test were compared between the two groups. Patients were followed for 1 year to monitor adverse reactions and the occurrence of adverse cardiovascular events. Results:The effective treatment rate in the observation group was significantly higher than that in the control group [90.63% (29/32) vs. 70.97% (22/31), χ2 = 3.95, P < 0.05). Prior to treatment, there were no statistically significant differences between the two groups regarding blood lipid levels, cardiac ultrasound indicators, serum levels of NT-proBNP, Hcy, and CRP, the distance covered in the 6-minute walk test, and the incidences of adverse reactions and adverse cardiovascular events (all P > 0.05). After treatment, both groups showed a reduction in total cholesterol and low-density lipoprotein cholesterol (both P < 0.05), with the observation group demonstrating significantly lower levels ( t = 10.54, 14.01, both P < 0.001). Additionally, both groups showed an increase in high-density lipoprotein cholesterol ( P < 0.05), but the observation group achieved significantly higher levels ( t = -14.07, P < 0.001). Both groups also exhibited an increase in left ventricular ejection fraction ( P < 0.05), with a greater improvement in the observation group ( t = -2.34, P < 0.05). The left ventricular end-diastolic diameter decreased in both groups ( P < 0.05), but the observation group had a smaller diameter ( t = 2.78, P < 0.05). Levels of NT-proBNP, Hcy, and CRP decreased in both groups (all P < 0.05), with the observation group showing significantly lower levels ( t = 6.55, 3.94, 6.38, all P < 0.001). Finally, the distance covered in the 6-minute walk test increased in both groups ( P < 0.05), with the observation group covering a greater distance ( t = -4.32, P < 0.001). Conclusions:High-dose rosuvastatin can effectively improve lipid metabolism and left ventricular function in patients with T2DM complicated by CHD. It significantly reduces levels of NT-proBNP, Hcy, and CRP, enhances exercise capacity, and demonstrates high safety, indicating a high potential for clinical application.

Objective To address the personalized differences in motion gait between stroke patients and healthy older adults,as well as the issue of abnormal gait recognition,a deep learning fusion-based approach is proposed to effectively improve the accuracy of abnormal gait recognition.Methods A model fusing convolutional neural networks(CNN)and bidirectional long short-term memory networks(BiLSTM)was adopted,with the introduction of a residual network(ResNet).Unilateral ankle joint movement data at different walking speeds within a comfortable range were collected from healthy older adults and stroke patients.Signals from inertial sensors and electromyography sensors were used as inputs,while gait features were analyzed and gait differences between the two groups were compared.The effectiveness of the model was validated by comparing the classification performance of traditional deep learning models and CNN-ResNet-BiLSTM models with different layer combinations in terms of abnormal gait recognition accuracy.Results The CNN-ResNet-BiLSTM model,which introduced residual connectivity,performed excellently in abnormal gait recognition.Compared with traditional deep learning models such as the gated recurrent unit(GRU)and long short-term memory network(LSTM),its prediction accuracy was improved by 13.6％and 8.36％,respectively.Additionally,compared with other model combinations,this model achieved an overall accuracy of 97.78％.Conclusions The algorithm proposed in this study can be applied to stroke-related abnormal gait detection,providing technique support for the early diagnosis and precise monitoring of such diseases.

Objective:To investigate the effects of different doses of rosuvastatin on lipid metabolism and left ventricular function in patients with type 2 diabetes mellitus (T2DM) accompanied by coronary heart disease (CHD).Methods:A prospective study was conducted involving 63 patients with T2DM accompanied by CHD who were treated at Jinan 2 nd People's Hospital and The Fifth People's Hospital of Jinan from January 2022 to June 2023. In a randomized case-control study, patients were assigned to either a control group ( n = 31, receiving 10 mg/d of rosuvastatin) or an observation group ( n = 32, receiving 20 mg/d of rosuvastatin) using a random number table method. After 8 weeks of treatment, the therapeutic effects were evaluated, and blood lipid levels and left ventricular function were recorded before and after treatment. Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), homocysteine (Hcy), C-reactive protein (CRP), and the distance covered in a 6-minute walk test were compared between the two groups. Patients were followed for 1 year to monitor adverse reactions and the occurrence of adverse cardiovascular events. Results:The effective treatment rate in the observation group was significantly higher than that in the control group [90.63% (29/32) vs. 70.97% (22/31), χ2 = 3.95, P < 0.05). Prior to treatment, there were no statistically significant differences between the two groups regarding blood lipid levels, cardiac ultrasound indicators, serum levels of NT-proBNP, Hcy, and CRP, the distance covered in the 6-minute walk test, and the incidences of adverse reactions and adverse cardiovascular events (all P > 0.05). After treatment, both groups showed a reduction in total cholesterol and low-density lipoprotein cholesterol (both P < 0.05), with the observation group demonstrating significantly lower levels ( t = 10.54, 14.01, both P < 0.001). Additionally, both groups showed an increase in high-density lipoprotein cholesterol ( P < 0.05), but the observation group achieved significantly higher levels ( t = -14.07, P < 0.001). Both groups also exhibited an increase in left ventricular ejection fraction ( P < 0.05), with a greater improvement in the observation group ( t = -2.34, P < 0.05). The left ventricular end-diastolic diameter decreased in both groups ( P < 0.05), but the observation group had a smaller diameter ( t = 2.78, P < 0.05). Levels of NT-proBNP, Hcy, and CRP decreased in both groups (all P < 0.05), with the observation group showing significantly lower levels ( t = 6.55, 3.94, 6.38, all P < 0.001). Finally, the distance covered in the 6-minute walk test increased in both groups ( P < 0.05), with the observation group covering a greater distance ( t = -4.32, P < 0.001). Conclusions:High-dose rosuvastatin can effectively improve lipid metabolism and left ventricular function in patients with T2DM complicated by CHD. It significantly reduces levels of NT-proBNP, Hcy, and CRP, enhances exercise capacity, and demonstrates high safety, indicating a high potential for clinical application.

Objective To analyze the biomechanical effects of gravity loading countermeasure garment on human lumbar intervertebral disc in microgravity environment. Methods Based on CT images of a healthy adult volunteer, the finite element model of L4-5 vertebrae was established. Through the empty load and 400 N axial loading for 4 hours on lumbar finite element model, the biomechanical effect of the non-intervention and gravity loading countermeasure garment were simulated respectively in microgravity environment. Results The central pore pressure, radial displacement and water content of the human lumbar intervertebral disc increased with time in microgravity environment. In the case of wearing gravity loading countermeasure garment, the central pore pressure, axial stress, radial displacement and water content of the lumbar intervertebral disc were reduced after 72 hours of cyclic loading compared with the non-intervention group. Conclusions Wearing gravity loading countermeasure garment can help astronauts to prevent the adverse effects of microgravity on the spine to some extent in microgravity environment.

Objective To explore the four tumor markers of alpha-fetoprotein ( AFP ), α-L-fucosidase( AFU), carbohydrate antigen 199 ( CA199) and carcinoembryonic antigen ( CEA) and their combined use for primary hepatocellular carcinoma (HCC) diagnosis and treatment value. Methods From February 2016 to August 2018,92 patients with primary hepatocellular carcinoma (HCC group),79 patients with benign liver disease (chronic hepatitis and cirrhosis group) and 99 healthy adults (control group) were selected as subjects. The serum levels of four tumor markers in different populations were compared. Results The serum levels of four tumor markers ( AFP ( 192. 4 ± 89. 3) μg／L、AFU( 78. 6 ± 25. 8) U／L、CA199 (107. 2 ± 59. 5) U／mL、 CEA ( 37. 9 ± 14. 9) μg／L) were significantly higher than those of benign liver disease group(AFP( 17. 4 ± 6. 3) μg／L、AFU( 35. 4 ± 17. 2) U／L、CA199( 29. 3± 15. 2) U／mL、CEA( 4. 9 ±1. 7) μg／L) and normal people( AFP(4. 8±1. 1) μg／L、AFU(12. 2±3. 6) U／L、CA199( 6. 4± 2. 3) U／mL、CEA(1. 8±0. 4) μg／L) . There differences had significant ( all P＜0. 05) . The abnormal rate of single factor in hepatocellular carcinoma group ( AFP 84. 8%, AFU 52. 2%, CA199 41. 3%, CEA35. 9%) was significantly higher than that in benign liver disease group ( AFP 15. 2%, AFU 19. 0%, CA19916. 5%, CEA13. 9%) and normal group (AFP 4. 0%,AFU 5. 0%,CA199 3. 0%,CEA 6. 0% ug／L),the difference was statistically significant ( all P＜0. 05) . The highest sensitivity was AFP ( 84. 8%) and the highest specificity was AFP and CA199 (91. 0%). The sensitivity of combined detection was 94. 6% higher than that of single index ( AFP 84. 8%, AFU52. 2%, CA199 41. 3%, CEA35. 9%) . Conclusion The combined detection of AFP,AFU,CA199 and CEA can increase the sensitivity of diagnosis of hepatocellular carcinoma and reduce the rate of missed diagnosis, which will be beneficial to the early diagnosis and treatment of hepatocellular carcinoma.

Objective To investigate the clinical value of joint detection of six tumor markers in patients with colorectal cancer. Methods Eighty?six patients with colorectal cancer were included in the study group,86 healthy subjects were selected as the control group at the same period. The difference of tumor markers in different groups,tumor stages and prognosis were compared. Results The levels of carcinoembryonic antigen (CEA),carbohydrate antigen 19?9 (CA19?9),carbohydrate antigen 242 (CA242),carbohydrate antigen 72?4 ( CA72?4) , carbohydrate antigen 125 ( CA125 ) and carbohydrate antigen 50 ( CA50 ) in study group were significantly higher than those in the control group (CEA: (22. 5±6. 2)μg/L vs. (2. 2±1. 0)μg/L;CA19?9:(95. 7±27. 3) U/ml vs. (17. 1±9. 5) U/ml;CA242:(29. 5±8. 3) U/ml vs. (6. 0±2. 7) U/ml;CA72?4:(21. 6 ±5. 1) U/ml vs. (3. 6±1. 2) U/ml;CA125:(95. 4±32. 8) U/ml vs. (18. 9±8. 4) U/ml;CA50:(51. 8±20. 6)μg/L vs. (8. 3±3. 7)μg/L,t=29. 98,25. 22,24. 97,31. 86,20. 95,19. 27,P<0. 05). Among the single index detections,the sensitivity and negative predictive value of CA72?4 were the highest ( 61. 6%, 68. 3%) , the specificity of CA19?9 was the highest( 91. 9%) ,the positive predictive value of CEA was the highest ( 80. 4%) . The sensitivity,positive predictive value and negative predictive value of the joint detection were all higher than those in each single index detection (80. 3%,87. 3%,74. 1%). The levels of CEA,CA19?9,CA242,CA72?4, CA125 and CA50 in patients with stage III and IV were significantly higher than those in patients with stageⅠandⅡ(CEA:(32. 7±7. 1)μg/L vs. (15. 9±4. 4)μg/L;CA19?9:(127. 8±33. 7) U/ml vs. (52. 5±13. 8) U/ml;CA242:(40. 3±12. 7) U/ml vs. (23. 5±8. 6) U/ml;CA72?4:(37. 6±10. 2) U/ml vs. (13. 6±4. 1) U/ml;CA125:(128. 9±38. 4) U/ml vs. (59. 7±12. 8) U/ml;CA50:(88. 3±23. 7)μg/L vs. (41. 8±15. 6)μg/L,t=13. 04,13. 32,7. 11,14. 06,10. 99,10. 64,P<0. 05) . The levels of CEA,CA19?9,CA242,CA72?4,CA125 and CA50 in the recurrent metastasis group were significantly higher than those in the non?recurrent metastasis group ( CEA:( 37. 7 ± 8. 6 ) μg/L vs. ( 3. 8 ± 1. 7 ) μg/L;CA19?9:( 110. 5 ± 29. 4 ) U/ml vs. ( 25. 5 ± 13. 8 ) U/ml;CA242:( 33. 6 ± 10. 3 ) U/ml vs. ( 15. 5 ± 6. 6 ) U/ml;CA72?4:( 33. 1 ± 15. 3 ) U/ml vs. ( 9. 3 ± 3. 0 ) U/ml;CA125:(113. 4±31. 7) U/ml vs. (28. 7±7. 8) U/ml;CA50:(55. 4±14. 6)μg/L vs. (16. 8±9. 6)μg/L,t=29. 04,18. 31,9. 86,11. 47,19. 28,14. 65,P<0. 05) . Conclusion The joint detection of six markers can further improve the sensitivity, positive predictive value and negative predictive value of diagnosis, and can provide a more reliable basis for the auxiliary diagnosis of colorectal cancer.

Objective To investigate the role of the QQ group follow up of nursing education on patients with nasopharyngeal carcinoma after radiotherapy in patients after they discharged. Methods Thirty patients with nasopharyngeal carcinoma hospitalized from January to December 2013 in our department were set as control group and another 30 patients with NPC hospitalized from January to December 2014 in our department were assined to in the experiment group. Patients of two group received health education before discharge . The controls were followed up on phone and the experimental group received QQ group follow up of education for one year, besides phone follow-up. The two groups were compared in terms of incidence of adverse reactions one year after discharge. Results One year after discharge , the incidences of side effects in the experiment group were lowered than those in the control group , and the differences were siguificant difference ( all P < 0 . 05 ) . Conclusion The QQ group follow up of nursing education can reduce the incidence of adverse reactions by radiotherapy after discharge.

OBJECTIVETo investigate the relationship between the environmental tobacco smoke (ETS) and lung cancer by Meta-analysis.

METHODSWe used "lung cancer/lung neoplasm", "non-smoking/non-smoker", "China/Chinese", "case-control/case control", "risk factor", "environmental tobacco smoke/passive smoking" as key words, to search papers in databases including Chinese BioMedical Literature (CBM), China National Knowledge Internet (CNKI), Wanfang, Vip Citation Databases (VIP), PubMed and Web of Science databases, and collected the case-control studies on ETS and lung cancer among Chinese non-smokers from January 1999 to December 2013. A total of 129 research papers were collected. RevMan 5.2 software was used to calculate combined odds radio (OR) and 95% CI.

RESULTSQualified 18 literatures were included, total cases 6 145 and controls 8 132. Consolidated results showed that ETS exposure could increase the risk of lung cancer, combined OR (95% CI) = 1.52 (1.42-1.64). Stratified analysis showed that ETS exposure was found to be significantly associated with an increasing risk of the lung cancer on non-smoking women and men, and combined OR (95% CI) were 1.58 (1.42-1.75) and 1.34 (1.08-1.65), respectively; the ETS exposure from family or the working environment could increase the risk of lung cancer, and combined OR (95% CI) were 1.48 (1.20-1.82) and 1.38 (1.13-1.69) respectively; childhood exposure and adult exposure were no significant statistical significance, and combined OR (95% CI) were 1.37 (0.98-1.91), and 1.34 (0.97-1.85) respectively.

CONCLUSIONEnvironmental tobacco smoke exposure was a significant risk factor of lung cancer among non-smokers in China.